Best of 4th Annual Immunology Bootcamp in Conjunction With the Association for Women in Rheumatology National Conference
Immune-mediated inflammatory disease (IMID) is a group of clinically heterogeneous disorders, including rheumatoid arthritis, psoriasis, psoriatic arthritis, giant cell arteritis, systemic lupus erythematosus, and axial spondyloarthritis, that share a similar immunopathology. Recognizing the underlying immunopathological mechanisms of these disorders is essential for understanding how current and emerging therapies exert their effects as well as for incorporating these agents into optimal treatment strategies. In this CME activity, held during the Association of Women in Rheumatology National Conference, experts in the field examine common signaling pathways that underly IMID, evaluate the latest clinical evidence for available and emerging steroid-sparing therapies targeting these signaling pathways, discuss the latest recommendation and clinical evidence for treatment selection in these patients, as well as provide insight for the monitoring of disease activity and management of systemic manifestations to ensure comprehensive patient management.
Cost: FreeView Offer chevron_right
Free; 1.0 AMA PRA Category 1 Credit(s)™; The My Healio CME Dashboard keeps track of earned credits and saved activities; Personalized recommendations make finding your next activity easy; Over 50,000 of your colleagues know that earn credits is faster and easier with Healio CME
Immune-mediated inflammatory disease; IMID; Clinical hetergeneous disorders; rheumatoid arthritis; psoriasis; psoriatic arthritis; giant cell arteritis; systemic lupus erythematosus; axial spondyloarthritis; Association fo Women in Rheumatology National Conference; Rheumatic disease
Upon successful completion of this educational activity, participants should be better able to: -Examine common signaling pathways that underlie immune-mediated rheumatic diseases as well as the molecular targets of available and emerging immune-based therapies. -Evaluate the latest clinical evidence regarding available or emerging steroid-sparing options for patients with rheumatic disease. -Apply the latest recommendations and clinical evidence to treatment selection for patients with rheumatic disease. -Assess patients being treated for rheumatic disease for disease activity to ensure treatment to the desired clinical target. -Assess patients with IMID for systemic manifestations to ensure comprehensive patient management.
The intended audience for this activity is rheumatologists, internists, and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases.
Additional credit info
Provider Statement This continuing medical education activity is provided by Vindico Medical Education. Support Statement This activity is supported by educational grants from: AbbVie Inc.; Bristol-Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Lilly. Accreditation Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. This enduring material is approved for 1 year from the date of original release, October 31, 2020 to October 30, 2021.